Radiochemotherapy of cervical carcinoma. (Necessity of dosis reduction in chemotherapy);A méhnyakrák radiokemotérápiája (a kemoterápiás dózisredukció szükségessége)

Orvosi Hetilap

Volumn 147, Issue 28, 2006, Pages 1315-1320

  Póti, Zsuzsa ^a   Patyánik, Mihály ^a   Nemeskéri, Csaba ^a  

^a Onkoradiológiai Központ ^*  (Hungary)

Author keywords

Cervical cancer; Radiochemotherapy; Toxicity

Indexed keywords

CISPLATIN; ANTINEOPLASTIC AGENT;

ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL PROTOCOL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEGAVOLTAGE RADIOTHERAPY; PELVIS; PHOTON THERAPY; RADIATION DOSE; RADIATION SICKNESS; UTERINE CERVIX CARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; CARCINOMA; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; HUNGARY; MIDDLE AGED; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME; UTERINE CERVIX TUMOR;

ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HUNGARY; MIDDLE AGED; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 33750108395     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Ang, K. K.: Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: Are we addressing burning subjects? J. Clin. Oncol., 2004, 22, 4607-4659.
2. Arriagada, R., Goldstraw, P., Le Chevalier, T.: Management of non-small-cell lung cancer. In Oxford Textbook of Oncology Second Edition. Szerk.: Souhami, R., Oxford Universitiy Press, Oxford, N. Y. 2002, 2089-2110. old.
3. Eifel, P. J., Rose, P. G.: Chemotherapy and radiation therapy for cervical cancer. ASCO 2000 Educational Book. ASCO, Alexandria. 2000, 199-206. old.
4. Hreshchyshyn, M. M., Aron, B. S., Boronow, R. C. és mtsai: Hydroxyurea or placebo combined with radiation to treat stages IIB and IV cervical cancer confined to the pelvis. Int. J. Radiat. Oncol. Biol. Phys., 1979, 5, 317-372.
5. Kallman, R. F., Rapacchietta, D., Zaghloul, M. S.: Scheduledependent therapeutic gain from the combination of fractionated irradiation plus c-DDP and 5-FU or plus c-DDP and cyclophosphamide in C3H/Km mouse model systems. Int. J. Radiat. Oncol. Biol. Phys., 1991, 20, 227-232.
6. Karnofsky, D. A., Burchenal, J. H.: The clinical evaluation of chemotherapeutic agents. In Evaluation of chemotherapeutic agents. Szerk.: McLoad, C. M. Columbia University Press, New York. 1949, 191-205. old.
7. Keys, H. M., Bundy, B. N., Stehman, F. B. és mtsai: Cisplatin, radiation, and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N. Engl. J. Med., 1999, 340, 1154-1161.
8. Mayer Á.: Brachyterápia tegnap és ma. Magy. Onkol., 1998, 42, 5-8.
9. Mayer Á.: Radioterápia az ezredfordulón. Orv. Hetil., 1999, 140, 1875-1880.
10. Mayer Á.: Hoterápia és etikai kérdései. Magyar. Orvos, 2001, 9, 45-46.
11. Mayer, Á., Nemeskeri, C., Petnehazi, C. és mtsai: Primary radiotherapy of stage IIA/B-IIIB cervical carcinoma. A comparison of continuous versus sequential regimens. Strahlenther Onkol., 2004, 180, 209-215.
12. Morris, M., Eifel, P. J., Lu, J. és mtsai: Pelvic radiation with concurrent chemotherapy compared with pelvic and paraaortic radiation for high-risk cervical cancer. N. Engl. J. Med., 1999, 340, 1137-1143.
13. National Cancer Institute: Clinical Announcement. Bethesda, MD, United State Department of Health and Human Services, Public Health Service, February, 1999.
14. National Cancer Institute Common Terminology Criteria for Adverse Events v 3.0 (CTCAE). Cancer Therapy Evaluation Program. Released December 2003.
15. Martinz, S., Köhler, C., Jürgen, F. és mtsai: Uterus necrosis after radiochemotherapy in two patients with advanced cervical cancer. Strahlenther Onkol., 2006, 182, 45-51.
16. Peters, W. A. I., Liu, P. Y., Barrett, R. és mtsai: Cisplatin, 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive therapy in high-risk, early-stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: Report of Phase III Intergroup Study. Gynecol. Oncol., 1999, 72, 443. (abstr).
17. Rose, P. G., Bundy, B. N., Watkins, E. B. és mtsai: Concurrent cisplatin-based chemotherapy and radiotherapy for locally advanced cervical cancer. N. Engl. J. Med., 1999, 340, 1144-1153.
18. Rotman, M., Aziz, H., Eifel, P. J.: Irradiation of pelvic and paraaortic nodes in carcinoma of the cervix. Semin. Radiat. Oncol., 1994, 4, 23-9.
19. Rotman, M., Pajak, M., Choi, K. és mtsai: Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas: Ten-year treatment results of RTOG 79-20. JAMA, 1995, 274, 387-393.
20. Timotheadou, E., Gore, M. E.: Neoadjuvant chemotherapy for locally advanced cervical cancer. Eur. J. Cancer, 2003, 39, 2419-2421.
21. van der Zee, J., Gonzalez Gonzalez, D., van Rhoon, G. C. és mtsai: Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet, 2000, 355, 1119-1125.
22. Whitney, C. W., Sause, W, Bundy, B. N. és mtsai: Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study. J. Clin. Oncol., 1999, 17, 1339-1348.
23. Withers, H. R., Taylor, J. M. G., Maciejewski, B.: The hazard of accelerated tumorclonogen repopulation during radiotherapy. Acta Oncol., 1988, 27, 131-146.